Theremia, a French deep tech company focused on precision medicine, recently raised €3 million in a seed funding round led by Eurazeo and Salica Investments, with support from Entrepreneur First, BPIFrance, and several business angels. The company plans to use the funds to expand its scientific team and establish partnerships with medical institutes, aiming to refine its treatment personalization algorithm and accelerate deployment across Europe.
Designed to address the limitations of standardised treatments, which are often developed for typical patient profiles, Theremia’s AI-powered platform allows medical treatments to be adjusted based on each patient’s characteristics. By tailoring treatment parameters such as dosage, frequency, and drug formulation, Theremia seeks to improve effectiveness while reducing side effects, thereby supporting patient adherence. The company cites that around 60% of patients discontinue their treatments due to adverse effects or insufficient results.
Theremia collaborates closely with healthcare practitioners, particularly in areas like neurology and psychiatry, to continuously refine its algorithms. This approach is intended to ensure that its models are scientifically sound and aligned with the nuances of specific conditions. For drug developers, Theremia’s platform facilitates the collection of real-world data, which can support demonstrating the effectiveness of treatments for specific patient subgroups—a growing requirement in value-based healthcare.
Led by Iris Maréchal, a former consultant specialising in public health, and Chloé Geoffroy, a pharmacist and doctor in neuroscience, Theremia’s team includes experts from various scientific and technological fields who are dedicated to advancing the platform’s capabilities in precision medicine.
